Our test can help identify patients that will benefit from therapy intensification

Our AI biomarkers can prognosticate long-term outcomes and predict therapeutic benefit to enable localized prostate cancer therapy personalization.

Five phase III randomized trials were used to develop and validate prognostic and predictive AI biomarkers.

Artera’s multi-modal AI was developed with over 16,000 digitized histopathology slides from over 5,000 patients.

Our science has been featured in a number of key conferences
    asco genitourinary cancers symposiom logo
    Osama Mohamad, MD

    Osama Mohamad, MD

    University of California San Francisco

    Dr. Mohamad discusses the development and validation of a multimodal artificial intelligence (MMAI)-derived prognostic biomarker in localized prostate cancer. The biomarker was shown to consistently outperform the standard NCCN risk stratification tool.

    ASCO GU 2022 link

    asco genitourinary cancers symposiom logo
    Osama Mohamad, MD

    Daniel Spratt, MD

    Case Western Reserve University

    Dr. Spratt discusses how an MMAI-derived predictive biomarker is able to discriminate between patients with intermediate-risk prostate cancer who would or would not benefit from adding ADT to RT.

    ASCO GU 2022 link

    2022 asco annual meeting logo
    Osama Mohamad, MD

    Mack Roach, MD, FASTRO, FASCO

    University of California San Francisco

    Dr. Roach discusses how the performance of the multimodal artificial intelligence (MMAI)-derived prognostic biomarker is comparable between African American and non-African American subgroups.

    ASCO 2022 link